Nicotine Gum at 40: The Accidental Cessation Aid That Changed Everything
When nicotine gum was first developed in the 1970s, nobody wanted it—not regulators, not doctors, not smokers. Four decades later, it has helped tens of millions quit. The story of its improbable journey to legitimacy.
In 1967, a Swedish physiologist named Ove Fernö, who worked for a pharmaceutical company studying nicotine's effects on the nervous system, had an idea that struck most of his colleagues as absurd: what if you could give smokers nicotine without the smoke? Fernö had noticed that submariners in the Swedish navy, unable to smoke during long deployments, would switch to oral snuff to manage their nicotine cravings. He reasoned that a pharmaceutical-grade nicotine delivery product could decouple the addiction from the lethal delivery system. His employer, Leo AB, was unconvinced. So was the medical establishment. So were regulators. It would take more than a decade for nicotine gum to reach the market, and another decade for it to be taken seriously as a medical intervention. The story of nicotine replacement therapy's journey from crackpot idea to pharmacy staple is a case study in how medical innovation happens—slowly, reluctantly, and against the grain of prevailing assumptions.
The scientific and regulatory obstacles Fernö faced were formidable. In the 1970s, nicotine addiction was not widely recognized as a medical condition. The dominant model of smoking was behavioral—people smoked because they had a 'smoking habit,' not because they were dependent on a drug. The idea of treating smoking with nicotine struck many as absurd, akin to treating alcoholism with ethanol patches. The FDA had no regulatory pathway for a nicotine product that wasn't a tobacco product, and the pharmaceutical industry had no template for a cessation aid that competed with over-the-counter gum. Fernö and his collaborators at what would become Pharmacia spent years developing a formulation that delivered nicotine slowly enough to avoid the addictive rush of smoking but quickly enough to relieve cravings—the polacrilex resin complex that remains the basis of nicotine gum today. They tested it on themselves, chewing prototype gum so unpleasant that Fernö later described it as 'like chewing pepper-flavored rubber.'
The clinical trials that eventually convinced regulators were a methodological breakthrough in their own right. Measuring smoking cessation required new outcome definitions (what qualifies as 'quit'?), new biochemical verification methods (measuring carbon monoxide in exhaled breath to confirm abstinence), and new trial designs that accounted for the high relapse rates characteristic of addiction treatment. The earliest trials showed modest but statistically significant effects—roughly double the quit rates of placebo gum—which was enough for regulatory approval in Switzerland and the UK in the late 1970s, but not enough to convince the FDA, which demanded larger and longer trials. Nicotine gum didn't receive U.S. approval until 1984, nearly two decades after Fernö's initial insight, and didn't become available over-the-counter until 1996.
The impact of nicotine gum on the smoking cessation landscape has been transformative, albeit more gradually than proponents hoped. NRT products—gum, patches, lozenges, inhalers, and nasal sprays—are now used by millions of smokers annually in quit attempts, and the evidence base supporting their efficacy is among the most robust in all of behavioral medicine. Cochrane reviews consistently find that NRT increases the odds of quitting by 50–70% compared to placebo or no treatment. But the absolute quit rates remain frustratingly low—typically 7–10% sustained abstinence at one year for NRT alone, rising to 15–20% when combined with behavioral support. The 'magic bullet' that Fernö and his successors hoped for has turned out to be a modestly effective tool that helps some smokers some of the time, a reality that has shaped the ongoing search for better alternatives.
The most important legacy of nicotine gum may not be the product itself but the conceptual framework it established: the idea that nicotine dependence is a treatable medical condition, that substituting a cleaner nicotine source for a dirtier one is valid therapy, and that public health should prioritize harm reduction over moral purity. These ideas were revolutionary when Fernö first proposed them and remain contested today. But they've become the intellectual foundation for everything from e-cigarette harm reduction to nicotine pouch regulation to the emerging recognition that some forms of nicotine use, in some populations, may represent a tolerable public health outcome in a world where the alternative is continued smoking.
Nicotine gum also transformed the economics of cessation. Before NRT, quitting was essentially unsupported for most smokers—counseling was scarce, pharmacotherapy didn't exist, and the cold-turkey paradigm reigned. NRT created a market, which created distribution networks (pharmacies, supermarkets, online retailers), which created access at scale. The over-the-counter switch in 1996 was particularly consequential: it removed the prescription barrier, reduced cost, and signaled that nicotine dependence was a condition that individuals could and should manage proactively. Critics note that the pharmaceutical industry profited handsomely from this market creation, and that NRT has been marketed in ways that overstate its effectiveness. Both critiques are valid. Neither diminishes the millions of quitters for whom an accessible, evidence-based cessation aid made the difference between another decade of smoking and a smoke-free life.
Four decades after nicotine gum's debut, the cessation landscape Fernö helped create is being disrupted by products—e-cigarettes, heated tobacco, nicotine pouches—that operate outside the pharmaceutical framework. These products, developed and marketed by the tobacco industry rather than the pharmaceutical industry, raise the same question Fernö faced in 1967: is it acceptable to maintain nicotine dependence if doing so eliminates smoke exposure? The answer, then and now, divides the public health community. But the fact that the question is even being asked, seriously, at the highest levels of global health governance is a measure of how far we've come from the era when smoking was considered a 'habit' and giving nicotine to smokers was considered a joke. Ove Fernö died in 2016. His pepper-flavored rubber changed the world.
